Cipla India announced that it had signed a royalty-free, non-exclusive voluntary licensing agreement with Eli Lilly USA to manufacture and commercialize this medication Baricitinib for Covid-19.

Baricitinib was issued a limited emergency usage consent from the Central Drugs Standard Control Organization (CDSCO), Ministry of Health, India. It can use it along with Remdesivir to treat suspected or lab-supported COVID-19 in hospitalized adults requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). 

This collaboration is a step further into Cipla’s attempts to boost access to crucial treatments for individuals affected by the outbreak. Cipla will leverage its extensive supply footprint to produce this treatment accessible to more markets and patients.

Commenting on the venture, Mr. Umang Vohra, MD, and Global CEO, Cipla India, stated, “Allowing access to high-quality therapy and medication is central to our goal of ‘Caring for life.’ 

He added, throughout the outbreak, Cipla India has been at the forefront Of COVID maintenance. Our partnership with Lilly is a presentation of our unwavering dedication to caring for individuals affected by COVID-19.